Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report

BACKGROUND: In the treatment of giant cell tumor of bone (GCTB), the efficacy and safety of denosumab, a receptor activator nuclear factor κ-B ligand inhibitor, has previously been demonstrated, especially for unresectable tumors. One of the current issues in denosumab treatment for unresectable GCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanikawa, Motoki, Yamada, Hiroshi, Sakata, Tomohiro, Mase, Mitsuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771493/
https://www.ncbi.nlm.nih.gov/pubmed/33408904
http://dx.doi.org/10.25259/SNI_439_2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771493/
https://www.ncbi.nlm.nih.gov/pubmed/33408904
http://dx.doi.org/10.25259/SNI_439_2020

Ejemplares similares